Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ninlaro

(Ixazomib Citrate)

Phase 2Small molecule

Ixazomib citrate is used to treat multiple myeloma, a type of blood cancer affecting plasma cells in the bone marrow. It works by blocking proteins that help cancer cells survive and grow.[1] Ninlaro is currently being investigated across 14 indications[3], with its most advanced program in Phase 2.[1]

Ninlaro is one of 338 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

14

Indications

30

Total Trials

6

Active Trials

337

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

LymphomaActive, not recruiting

POEMS SyndromeActive, not recruiting

AmyloidosisUnknown

Chronic Graft Versus Host DiseaseActive, not recruiting

Plasma Cell LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Multiple MyelomaUnknown

Acute Myeloid LeukemiaActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

POEMS SyndromePhase 1

Active, not recruiting

AmyloidosisPreclinical

Unknown

Chronic Graft Versus Host DiseasePhase 2

Active, not recruiting

Plasma Cell LeukemiaPhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Multiple MyelomaPreclinical

Unknown

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ninlaro

Tykerb

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Avastin

BBio-Thera Solutions

Prolia

Blenoxane

Bristol-Myers Squibb

Voltaren

Lupron

EEastern Cooperative Oncology Group

Spravato

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Kidney Cancer

NCT03587662

Q1 2028

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT02339922

Q1 2029

Phase 2Recruiting

Kaposi Sarcoma

NCT04305691

Clinical

Trials by Indication[1]

Multiple Myeloma18 trials

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03941860·1 enrolled

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT03457142·15 enrolled

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03506360·13 enrolled

Show 15 more trials

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Completed· Takeda logo

Takeda·Phase 3·NCT02181413·656 enrolled

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02504359·11 enrolled

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT02633059·33 enrolled

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Completed·UUniversity of Chicago·Phase 2·NCT02389517·42 enrolled

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02619682·30 enrolled

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Active, not recruiting·JJoseph Tuscano·Phase 1/2·NCT02542657·30 enrolled

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01718743·64 enrolled

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03770260·8 enrolled

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1·NCT00963820·60 enrolled

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT03399539·8 enrolled

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Completed·MMayo Clinic·Phase 1/2·NCT01864018·87 enrolled

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT03856112

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03202628·8 enrolled

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT02119468·32 enrolled

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03012880·80 enrolled

Kaposi Sarcoma1 trial

Trial of Ixazomib for Kaposi Sarcoma

Recruiting·AAIDS Malignancy Consortium·Phase 2·NCT04305691·41 enrolled

Urothelial Cancer1 trial

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT02420847·57 enrolled

Mantle Cell Lymphoma1 trial

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04047797·3 enrolled

Kidney Cancer1 trial

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03587662·30 enrolled

8 more indications

Plasma Cell Leukemia1 trial

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Completed·MMayo Clinic·Phase 2·NCT02547662·17 enrolled

POEMS syndrome1 trial

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Completed·MMayo Clinic·Phase 1·NCT02921893·21 enrolled

Lymphoma1 trial

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 1/2·NCT02481310·38 enrolled

Amyloidosis1 trial

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04847453·24 enrolled

Chronic Graft Versus Host Disease1 trial

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02513498·50 enrolled

Waldenstrom macroglobulinemia1 trial

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated·MMayo Clinic·Phase 2·NCT03506373·21 enrolled

Chronic Lymphocytic Leukemia1 trial

A Window Study of Ixazomib in Untreated Indolent B-NHL

Active, not recruiting·UUniversity of Washington·Phase 2·NCT02339922·33 enrolled

Recurrent Plasma Cell Myeloma1 trial

Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT01415882·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Ixazomib Citrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ixazomib Citrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ixazomib Citrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: 26s PROTEASOME Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

Related News